Brief: Neovacs Signs Agreement Allowing For Resumption Of Clinical Trials In China

Neovacs SA

18/03/2022 07:34

March 18 (Reuters) - Neovacs SA  ALNEV.PA :
    * SIGNS NEW AGREEMENT PAVING THE WAY FOR RESUMPTION OF
CLINICAL
TRIALS IN LUPUS
    * AGREEMENT ALLOWS THE RESUMPTION OF CLINICAL TRIALS IN
CHINA,
WHICH ARE FULLY SUPPORTED BY BIOSENSE GLOBAL
    * NEOVACS RETAINS FULL EXPLOITATION RIGHTS TO PRODUCT EXCEPT
IN
CHINA, WHERE BIOSENSE GLOBAL HAS GEOGRAPHICAL EXCLUSIVITY AND
WILL PAY MILESTONES, ROYALTIES IN CASE OF COMMERCIALIZATION
    * JOINT STRATEGIC COMMITTEE WILL BE SET UP IN COMING WEEKS
TO
DEFINE CLINICAL STRATEGY IN CHINA

Source text for Eikon:  ID:nACT73614 
Further company coverage:  ALNEV.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))